GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcellx Inc (NAS:ACLX) » Definitions » Total Liabilities

Arcellx (Arcellx) Total Liabilities : $283.1 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Arcellx Total Liabilities?

Arcellx's Total Liabilities for the quarter that ended in Mar. 2024 was $283.1 Mil.

Arcellx's quarterly Total Liabilities declined from Sep. 2023 ($348.09 Mil) to Dec. 2023 ($339.75 Mil) and declined from Dec. 2023 ($339.75 Mil) to Mar. 2024 ($283.12 Mil).

Arcellx's annual Total Liabilities declined from Dec. 2021 ($250.30 Mil) to Dec. 2022 ($108.86 Mil) but then increased from Dec. 2022 ($108.86 Mil) to Dec. 2023 ($339.75 Mil).


Arcellx Total Liabilities Historical Data

The historical data trend for Arcellx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcellx Total Liabilities Chart

Arcellx Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
76.33 121.41 250.30 108.86 339.75

Arcellx Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 319.23 329.86 348.09 339.75 283.12

Arcellx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Arcellx's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=118.238+(50.841+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+170.673+0)
=339.8

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=825.132-485.38
=339.8

Arcellx's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=107.901+(47.685+15.468
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+112.068+0)
=283.1

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=779.695-496.573
=283.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arcellx Total Liabilities Related Terms

Thank you for viewing the detailed overview of Arcellx's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcellx (Arcellx) Business Description

Traded in Other Exchanges
N/A
Address
25 West Watkins Mill Road, Suite A, Gaithersburg, MD, USA, 20878
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.
Executives
Michelle Gilson officer: Chief Financial Officer 25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG MD 20878
Christopher Heery officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Rami Elghandour director, officer: See Remarks 15 BARCELONA CIR, REDWOOD CITY CA 94065
Jill Carroll director C/O APPLIED GENETIC TECHNOLOGIES CORP., 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Olivia C Ware director 11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Sr One Capital Management, Llc 10 percent owner 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Sr One Co-invest Ii Manager, Llc 10 percent owner 985 OLD EAGLE SCHOOL ROAD, SUITE 511, WAYNE PA 19087
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093